|
5 Companies |
|
4 Products |
|
4 Products |
|
4 Mechanisms of Action |
|
0 Trials |
|
12 News |
|
- || mitomycin / Generic mfg.
Trial completion, Surgery: Oculusgen (Ologen) Glaucoma MMC Control in Estonia (clinicaltrials.gov) - Jun 27, 2017
P3, N=20, Completed, Sponsor: Pro Top & Mediking Company Limited
Recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Combination therapy: Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma (clinicaltrials.gov) - Dec 2, 2016
P1, N=40, Completed, Sponsor: Massachusetts Eye and Ear Infirmary
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Trial completion: VEGA: Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (clinicaltrials.gov) - Sep 12, 2016
P3, N=54, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Enrollment closed: VEGA: Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (clinicaltrials.gov) - Jun 27, 2016
P3, N=54, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma (clinicaltrials.gov) - Jan 6, 2016
P4, N=18, Completed, Sponsor: Ruijin Hospital
- |||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Enrollment open: VEGA: Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (clinicaltrials.gov) - Apr 18, 2015
P3, N=54, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
New P3 trial: VEGA: Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (clinicaltrials.gov) - Mar 26, 2015
P3, N=54, Not yet recruiting, Sponsor: Bayer
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Phase classification, Combination therapy: Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma (clinicaltrials.gov) - Nov 10, 2014
P1, N=40, Active, not recruiting, Sponsor: Massachusetts Eye and Ear Infirmary
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=20, Completed, Sponsor: University of Luebeck
Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 Recruiting --> Completed
- ||||| Triesence (triamcinolone acetonide injectable suspension) / Novartis
Enrollment change, Surgery: Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? (clinicaltrials.gov) - Dec 20, 2012
P2/3, N=77, Completed, Sponsor: Wills Eye
Recruiting --> Completed N=172 --> 77
- ||||||| Triesence (triamcinolone acetonide injectable suspension) / Novartis
Trial completion, Surgery: Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? (clinicaltrials.gov) - Dec 20, 2012
P2/3, N=77, Completed, Sponsor: Wills Eye
N=172 --> 77 Active, not recruiting --> Completed
- Trial termination, Surgery: Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube (clinicaltrials.gov) - Dec 19, 2012
P=N/A, N=40, Terminated, Sponsor: Wills Eye
Active, not recruiting --> Completed Active, not recruiting --> Terminated; kerasys had more erosions than tutoplast